Skip to main content
. 2022 May;63(5):727–734. doi: 10.2967/jnumed.121.262468

TABLE 3.

Adverse Events After Onset of Treatment, Related or Unrelated

Laboratory-based AEs
Hematology Kidney Liver Pancreatobiliary
WBCs ANC Hb PLTs sCr T Bil AST ALT GGT ALP Amylase New G3/G4 AE (laboratory)
Patient no. General B F B F B F B F B F B F B F B F B F B F B F
1 Acute respiratory distress, tumor-related (G5) G3 G2 G3 G2 G1 G1 Yes
2 Tumor pain (G2) G1 G1 G1 G1 G1 G1 No
3 None G1 G1 G1 G1 G1 No
4 Tumor progression, (G5) G1 G2 G1 G3 G3 G1 G3 G2 G3 G1 G1 G3 G2 G2 Yes
5 Tumor progression (G5) G1 G2 G1 G3 G1 G2 G2 G4 G1 G4 G3 G4 G3 G3 Yes
6 Pneumonia*, tumor progression (G5) G1 G3 G1 G3 G2 G2 G2 G3 G1 G2 Yes
7 Fever, urinary tract infection* G1 G2 No
8 None G1 G1 G1 G1 No
9 None G1 G1 G3 G3 G2 G2 No
Any new AE (%) 1 (11%) 1 (11%) 3 (33%) 6 (67%) 3 (33%) 3 (33%) 3 (33%) 1 (11%) 3 (33%) 1 (11%)
Any new G3/G4 AE (%) 1 (11%) 4 (44%) 1 (11%) 1 (11%) 1 (11%) 2 (22%)
*

Relation to 90Y-FAPI-46 was ruled out.

AE = adverse event; WBCs = white blood cells; ANC = absolute neutrophil count; Hb = hemoglobin; PLTs = platelets (thrombocytes); sCr = serum creatinine; T Bil = total bilirubin; AST = aspartate transaminase; ALT = alanine transaminase; GGT = γ-glutamyltransferase; ALP = alkaline phosphatase; B = baseline; F = follow-up.

G grade is defined as per CTCAE, version 5.0.